STRO - Sutro Biopharma's Lead Ovarian Cancer Candidate Is A Game Changer Analyst Sees Huge Upside | Benzinga
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside.
The analysts Jay Olson and Matthew Hershenhorn view Sutro as a unique clinical-stage company pioneering the development of next-generation antibody-drug conjugates (ADCs), a growing area of strategic interest.
Lead asset luveltamab tazivibulin (luvelta) is a FolRα-targeting ADC for platinum-resistant ovarian cancer (PROC), competing against ImmunoGen Inc's (NASDAQ: IMGN) Elahere.
The analysts initiate with an Outperform rating and a price target of $10.
Luvelta represents a promising ADC (Antibody-Drug Conjugate) aimed at targeting folate receptor alpha (FolRα) and potentially gaining a competitive edge ...